Guardant360 CDx Approval Validates Oncology Core but Leaves Shield Overhang Unresolved

What happened

The FDA approved Guardant's Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS (zongertinib), the first targeted therapy for HER2-mutant advanced NSCLC. This bolsters Guardant's oncology franchise and biopharma revenue, but does not address the fundamental overhang: Shield's colorectal screening ramp faces competitive pressure from Abbott/Exact, pricing risk from ADLT reset, and the company still burns ~$230M FCF annually. At ~$110, the stock prices in perfect execution of Shield and sustained 30%+ growth. The CDx win is incremental and likely already discounted; the core thesis remains cautious on Shield's economics and valuation.

Implication

The Guardant360 CDx approval validates Guardant's liquid biopsy platform and adds a new revenue stream from biopharma partnerships. However, the core thesis remains cautious: Shield's economics face pricing and competitive risks, and Guardant still burns ~$230M FCF annually. At ~$110 (~14x 2026E sales), the stock prices in perfect execution. This news does not justify the current multiple. Maintain underweight until Shield risk clears at a lower entry price ($80 or below).

Thesis delta

The CDx win strengthens the oncology franchise narrative but leaves the Shield risk unchanged; the investment case still hinges on Shield's ability to achieve profitable scale without significant pricing erosion. No change to the bearish tilt.